Data / Drug companies / Boehringer Ingelheim RCV GmbH & Co KG
Boehringer Ingelheim RCV GmbH & Co KG: 17 products in the FDA NDC directory, labeler code 68594
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Boehringer Ingelheim RCV GmbH & Co KG (labeler code 68594) lists 17 products in the FDA National Drug Code Directory. By type: 10 bulk ingredients, 5 vaccines. Its main marketing category is drugs for further processing. The newest product started marketing on September 1, 2025.
The request: Watch Boehringer Ingelheim RCV GmbH & Co KG (FDA labeler code 68594): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 68594
- Products in commercial distribution
- 17
- Packages
- 17
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- December 10, 1990
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 7 | 41.2% |
| Bulk ingredients | 7 | 41.2% |
| Bulk ingredients for compounding | 3 | 17.6% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 10 | 58.8% |
| Vaccines | 5 | 29.4% |
| Drugs for further processing | 2 | 11.8% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Liquid | 7 | 41.2% |
| Injection, solution | 3 | 17.6% |
| Powder, for solution | 3 | 17.6% |
| Suspension | 2 | 11.8% |
| Powder | 1 | 5.9% |
| Solution | 1 | 5.9% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Trastuzumab deruxtecan | 68594-130 | Powder, for solution | Bulk ingredients | September 1, 2025 |
| Aldesleukin | 68594-070 | Powder | Drugs for further processing | March 30, 2025 |
| Alteplase | 68594-090 | Powder, for solution | Bulk ingredients | May 15, 2024 |
| Human papillomavirus type 18 l1 protein adsorbed | 68594-012 | Liquid | Drugs for further processing | January 22, 2024 |
| Human papillomavirus type 16 l1 protein adsorbed | 68594-010 | Liquid | Drugs for further processing | January 22, 2024 |
| Human papillomavirus type 11 l1 protein adsorbed | 68594-008 | Liquid | Drugs for further processing | January 22, 2024 |
| Human papillomavirus type 6 l1 protein adsorbed | 68594-006 | Injection, solution | Bulk ingredients | January 2, 2024 |
| Somatropin | 68594-040 | Injection, solution | Bulk ingredients for compounding | September 3, 2020 |
| Pegvaliase | 68594-060 | Liquid | Drugs for further processing | May 24, 2018 |
| Human parathyroid hormone | 68594-002 | Liquid | Bulk ingredients | October 31, 2014 |
| Mnb rlp2086 subfamily b protein | 68594-028 | Suspension | Drugs for further processing | October 29, 2014 |
| Mnb rlp2086 subfamily a protein | 68594-027 | Suspension | Drugs for further processing | October 29, 2014 |
| Teduglutide | 68594-001 | Solution | Bulk ingredients for compounding | June 1, 2012 |
| Teriparatide | 68594-030 | Injection, solution | Bulk ingredients | May 2, 2012 |
| Anakinra | 68594-050 | Liquid | Bulk ingredients | November 14, 2001 |
| Interferon beta-1b | 68594-080 | Powder, for solution | Bulk ingredients | July 23, 1993 |
| Interferon-gamma-1b | 68594-020 | Liquid | Bulk ingredients for compounding | December 10, 1990 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.